logo-loader

AIM ImmunoTech green-lit to import chronic fatigue syndrome drug into Argentina

Published: 00:12 23 Jun 2020 AEST

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive the Florida-based biotech has received approval from Argentinian regulators to import its myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) drug Ampligen.

Equels says the company recently got a nod from the FDA to export the drug to Argentina for commercial sale, adding that Ampligen is the only drug approved for severe CFS anywhere in the world.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

10 hours, 6 minutes ago